Citurgia Biochemicals Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, confirming adherence to applicable statutory provisions despite operational constraints caused by a prior trading suspension. The report, issued by M/s. Sumit Bajaj & Associates, highlights that the company has complied with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, except for specific delays in filings during the suspension period.

During the year under review, the trading in the equity shares of the listed entity was suspended. The company had filed an application for revocation of suspension with the Stock Exchange, and the suspension was subsequently revoked with effect from February 09, 2026. This suspension and related operational constraints were cited as reasons for delays in submitting the Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as well as delays in submitting the Annual Report and Financial Results for that period.

The practicing company secretaries identified three specific deviations from compliance timelines for the previous financial year. These included the non-submission of the Annual Secretarial Compliance Report within 60 days, a delay in submitting the Annual Report, and a delay in submitting Financial Results. In all instances, the action taken by the authorities was recorded as an advisory, with the potential for fines as may be levied by the Stock Exchange.

Management attributed these delays to the suspension of trading and the resulting operational challenges. The company stated that it is taking necessary steps to ensure timely compliance and submission of all applicable filings in the future. The report advised the company to strengthen its internal compliance and monitoring mechanisms to avoid recurrence of such delays.

Regarding the compliance status for FY26, the report confirmed that the listed entity has complied with Secretarial Standards issued by the Institute of Company Secretaries of India and has adopted and updated all applicable policies under SEBI Regulations. The company maintains a functional website with timely dissemination of documents. No directors were disqualified under Section 164 of the Companies Act, 2013, and the company does not have any subsidiaries or related party transactions during the year.

The report also noted that the company appointed a Chief Financial Officer on May 28, 2026, in compliance with Section 203 of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. There were no reportable events concerning the resignation of statutory auditors during the financial year.

Citurgia Biochemicals has appointed Mr. Kashi Nath Jha as its Chief Financial Officer and Key Managerial Personnel effective May 29, 2026. The appointment was approved by the Board of Directors during a meeting held on the same day, following a recommendation from the Nomination and Remuneration Committee. The decision was communicated to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Kashi Nath Jha brings extensive experience to the role, having spent 28 years in the field of Finance and Accounts. His expertise includes conducting feasibility studies, strategic financial planning, and the establishment of policies and mechanisms. He is also skilled in managing P&L operations and risk mitigation strategies.

The Board meeting, which commenced at 11:00 noon and concluded at 12:00 P.M. IST, formalized the appointment. The disclosure was made in compliance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Appointment Details